Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Participation as an Outcome in Multiple Sclerosis Falls-Prevention Research: Consensus Recommendation from the International MS Falls Prevention Research Network.
Celastrol Ameliorates EAE Induction by Suppressing Pathogenic T Cell Responses in the Peripheral and Central Nervous Systems.
Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.
Correlates of participation in meaningful activities among people with multiple sclerosis.
Hormonal and gender-related immune changes in multiple sclerosis.
Non pharmacological interventions for spasticity in multiple sclerosis.
IFN-γ-induced apoptosis of human embryonic stem cell derived oligodendrocyte progenitor cells is restricted by CXCR2 signaling.
Bi-Allelic TCRα or β Recombination Enhances T Cell Development but Is Dispensable for Antigen Responses and Experimental Autoimmune Encephalomyelitis.
Medical use of cannabis products : Lessons to be learned from Israel and Canada.
Conventional housing conditions attenuate the development of experimental autoimmune encephalomyelitis.
Dramatically changing rates and reasons for hospitalization in multiple sclerosis.
Immunity and inflammation in neurodegenerative diseases.
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Antigenic epitopes of MAP2694 homologous to T-cell receptor gamma-chain are highly recognized in multiple sclerosis Sardinian patients.
Imaging multiple sclerosis outside the brain.
Magnetic resonance spectroscopic findings of chronic lesions in two subtypes of multiple sclerosis: primary progressive versus relapsing remitting.
Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.
Disambiguating the optic nerve from the surrounding cerebrospinal fluid: Application to MS-related atrophy.
Lipopolysaccharide directly stimulates Th17 differentiation in vitro modulating phosphorylation of RelB and NF-κB1.
Potential of Urinary Metabolites for Diagnosing Multiple Sclerosis.
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis.
Investigation of Sequential Growth Factor Delivery during Cuprizone Challenge in Mice Aimed to Enhance Oligodendrogliogenesis and Myelin Repair.
Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis.
Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
Pages
« first
‹ previous
…
579
580
581
582
583
584
585
586
587
…
next ›
last »